| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/10/2004 | WO2003044057A3 Use of obg3 for promoting central nervous system remyelination |
| 06/10/2004 | WO2003037258A3 Methods and compositions for the treatment and diagnosis of pain disorders using 2047 |
| 06/10/2004 | WO2002090600A3 A method for regulating immune function in primates using the foxp3 protein |
| 06/10/2004 | US20040110956 Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them |
| 06/10/2004 | US20040110952 e.g., N-[1-(3-phenyl-3-[cyclopenytlacetylamino]propyl)-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide |
| 06/10/2004 | US20040110920 Novel g protein-coupled receptor protein and dna thereof |
| 06/10/2004 | US20040110840 Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 06/10/2004 | US20040110829 treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase dysphoric disorder (premenstrual syndrome), attention deficit disorder, with/without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa |
| 06/10/2004 | US20040110826 Alpha 2c-adrenoceptor antagonists comprising 1- (benzylamino)-1,2,4]triazolo[1,5-c]pyrimidine derivatives; Parkinson's disease, dyskinesias, antidepressants; hypotensive, antidiabetic agents; eating,sexual disorders |
| 06/10/2004 | US20040110810 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. |
| 06/10/2004 | US20040110809 di- and tricycle-substituted imidazolidine-, oxazolidine- and thiazolidine diones and thiones, e.g., 5-[p-(quinolin-3-yl)-alpha-hydroxybenzyl]-5-methylimidazolidinedione |
| 06/10/2004 | US20040110805 Sulfur compounds such as 4-[(4-{3-[(2-adamantylamino)sulfonyl]propoxy}phenyl)sulfonyl]- N-hydroxytetrahydro-2H-pyran-4-carboximide, used as antagonists for metalloenzyme and/or aggrecanase activity; tissue repair |
| 06/10/2004 | US20040110794 Novel piperidine derivatives as modulators of chemokine receptors |
| 06/10/2004 | US20040110793 Heterocyclo inhibitors of potassium channel function |
| 06/10/2004 | US20040110788 A 2-azabicyclo-[2.2.1]hept-7yl derivatives, treating schizophrenia, depression, anxiety, dementia, Alzheimer's disease, neurodegenerative disorders, Parkinson's disease, Huntington's disease, Tourette's syndrome; chemical intermediates |
| 06/10/2004 | US20040110779 Hydantoin derivsatives with affinity for somatostatin receptors |
| 06/10/2004 | US20040110778 A 3,10-diaza-benzo[e]azulene, 3,8,10-triaza-benzo[e]azulene, or 1,3a,6-triaza-as-indacene derivatives, used to treat anxiety, depression, a sleep disorder, or Alzheimer's dementia. |
| 06/10/2004 | US20040110768 (S)-3-(1H-indol-3-yl)-N-(1-methoxymethyl-cyclohexylmethyl)-2-methyl-2-[4-(4-nitro-phenyl)-oxazol-2-ylamino]-propionamide for example; cancer, psychological disorders, sexual disorders, eating disorders, inflammatory bowel disease, sleep disorders |
| 06/10/2004 | US20040110763 Pyrazolopyridine compound and pharmaceutical use thereof |
| 06/10/2004 | US20040110759 Inhibitors of IkB kinase (I Kappa B Kinase); treating various diseases including asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, cancer, infections, and cardiac infarct |
| 06/10/2004 | US20040110753 Tyrosine derivatives |
| 06/10/2004 | US20040110752 2-amino-5-((hetero)aryl)-thiazole derivatives; treatment of disorders such as cancer, immunologic disorders and allergic disorders, optionally in combination with other drugs such as immunosuppressants |
| 06/10/2004 | US20040110750 Ortho-diihydroxy- coumarin or 1,2--dihydroquinoline derivatives as catechol-O-methyltransferase enzyme inhibitors for Parkinson*s disease treatment |
| 06/10/2004 | US20040110746 Piperazinyl and diazapanyl benzamides and benzthioamides |
| 06/10/2004 | US20040110744 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists |
| 06/10/2004 | US20040110743 Aromatic amine or amide derivatives; neurodegenerative, brain, cardiovascular disorders; spinal cord injuries, encephalitis, cerebral palsy; cognition activators |
| 06/10/2004 | US20040110741 Substituted pyrazolyl compounds for the treatment of inflammation |
| 06/10/2004 | US20040110736 Cyclic derivatives as modulators of chemokine receptor activity |
| 06/10/2004 | US20040110734 Combinations for the treatment of inflammatory disorders |
| 06/10/2004 | US20040110728 Agonists and antagonists of sphingosine-1-phosphate receptors |
| 06/10/2004 | US20040110723 Modified psma ligands and uses related thereto |
| 06/10/2004 | US20040110715 Differs from nucleotide sequence of wild-type IFN alpha -17 gene, in that it comprises one or several SNPs (Single Nucleotide Polymorphism[s]); anticarcinogenic and antiproliferative agents; side effect reduction |
| 06/10/2004 | US20040110709 Genetic modification of the lung as a portal for gene delivery |
| 06/10/2004 | US20040110707 Method of treating neurological diseases |
| 06/10/2004 | US20040110706 Nucleic acid with point mutations, deletions, insertions and/or rearrangements ; hyperthermia, myasthenia, ataxia, neuropathic and inflammatory pain; Alzheimer*s, Parkinson's disease; schizophrenia, hyperekplexia, myotonias and arrhythmia |
| 06/10/2004 | US20040110692 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 06/10/2004 | US20040110690 Transporter peptide capable of translocating across biological membrane of pancreatic B-cells, hepatocytes, colon cells, muscle cells and/or lung cells; drug delivery; biochemical conjugation |
| 06/10/2004 | US20040110669 Destruction of prions using vibriolysin or variants thereof |
| 06/10/2004 | US20040110250 Materials and methods relating to protein aggregation in neurodegenerative disease |
| 06/10/2004 | US20040110180 Comprises enzymatic polypeptide for diagnosis, treatment and prevention of cardiovascular, immune system, nervous system, lipid and cell proliferative disorders; drug screening |
| 06/10/2004 | US20040110171 Identifying transcriptional regulators which control axonal guidance for use as treatments of age related neurodegenerative diseases |
| 06/10/2004 | US20040110164 L-methionine $g(g)-lyase with modified function |
| 06/10/2004 | US20040109907 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles |
| 06/10/2004 | US20040109866 Immonotherapy complex containing antigen, antibodies, epitopes; binding to receptors |
| 06/10/2004 | US20040109859 Method for the treatment of multiple sclerosis |
| 06/10/2004 | US20040109857 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 06/10/2004 | CA2589836A1 Target for therapy of cognitive impairment |
| 06/10/2004 | CA2507616A1 Highly stable pacap/vip-derived peptides |
| 06/10/2004 | CA2507597A1 Halothenoyl-cyclopropane-1-carboxylic acid derivatives |
| 06/10/2004 | CA2507158A1 Treatment of headache with antipsychotics delivered by inhalation |
| 06/10/2004 | CA2506948A1 Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor |
| 06/10/2004 | CA2503246A1 Compositions and methods for diagnosing and treating mood disorders |
| 06/10/2004 | CA2498566A1 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors |
| 06/09/2004 | EP1426375A2 Analgesic spiroindole derivatives |
| 06/09/2004 | EP1426374A1 Naphthyridine derivative |
| 06/09/2004 | EP1426373A1 Method for producing the anticholinergic agent tiotropium bromide |
| 06/09/2004 | EP1426370A1 Propanolamine derivative having 1,4 benzodioxane ring |
| 06/09/2004 | EP1426055A1 Targeted protein degradation vehicles (tpdvs), nucleic acid constructs encoding them and their use |
| 06/09/2004 | EP1426051A1 Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy |
| 06/09/2004 | EP1426050A1 Jnk inhibitors |
| 06/09/2004 | EP1426049A1 Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease |
| 06/09/2004 | EP1425403A1 Use of a lentiviral vector in the treatment of pain |
| 06/09/2004 | EP1425390A2 Materials and methods to promote repair of nerve tissue |
| 06/09/2004 | EP1425388A2 A method for isolating, culturing and differentiating intestinal stem cells for therapeutic use |
| 06/09/2004 | EP1425308A2 Polysaccharidic esters of retinoic acid |
| 06/09/2004 | EP1425286A1 Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of diseases |
| 06/09/2004 | EP1425284A2 Furo- and thienopyrimidine derivatives as angiogenesis inhibitors |
| 06/09/2004 | EP1425283A1 Novel 4-aminofuropyrimidines and the use thereof |
| 06/09/2004 | EP1425281A1 Chemical compounds |
| 06/09/2004 | EP1425280A2 Hetero-bicyclic crf antagonists |
| 06/09/2004 | EP1425277A2 Urea-compounds active as vanilloid receptor antagonists for the treatment of pain |
| 06/09/2004 | EP1425272A1 Optical isomers of an iloperidone metabolite |
| 06/09/2004 | EP1425256A1 Method for preparing unsaturated fatty hydroxy-acids and esters thereof, their use in pharmaceutical and/or cosmetic compositions |
| 06/09/2004 | EP1425035A1 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 06/09/2004 | EP1425031A2 Hdl for the treatment of stroke and other ischemic conditions |
| 06/09/2004 | EP1425030A2 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof |
| 06/09/2004 | EP1425026A1 Pharmaceutical composition containing valeriana officinalis extract |
| 06/09/2004 | EP1425020A1 Methods and compositions for treating apoptosis associated disorders |
| 06/09/2004 | EP1425017A1 Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic |
| 06/09/2004 | EP1425014A1 Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators |
| 06/09/2004 | EP1425011A2 Enhancement of learning and memory and treatment of amnesia |
| 06/09/2004 | EP1425010A1 Substituted indoles and their use as integrin antagonists |
| 06/09/2004 | EP1425008A1 Use of substituted aminomethyl chromans in the treatment of movement disorders |
| 06/09/2004 | EP1425004A1 Use of compounds as functional antagonists to the central cannabinoid receptors |
| 06/09/2004 | EP1425001A1 Phenethanolamine derivatives for treatment of respiratory diseases |
| 06/09/2004 | EP1424998A1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| 06/09/2004 | EP1424973A1 Disposal system for transdermal dosage form |
| 06/09/2004 | EP1424957A2 Microfabricated nanopore device for sustained release of therapeutic agent |
| 06/09/2004 | EP1337535B1 Benzodiazepine derivatives as gaba a receptor modulators |
| 06/09/2004 | EP1299380B1 Indole derivatives useful for the treatment of cns disorders |
| 06/09/2004 | EP1246824B1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof |
| 06/09/2004 | EP1235797B1 Aralkyl-1,2-diamines having calcimimetic activity and preparation mode |
| 06/09/2004 | EP1212323B1 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 06/09/2004 | EP1202966B1 Piperidine alcohols |
| 06/09/2004 | EP1196176B1 Use of beta-napthoquinone derivatives for the manufacture of a medicament having an inhibiting effect on the release of glutamate by the brain |
| 06/09/2004 | EP1171441B1 Morphinoid compounds |
| 06/09/2004 | EP1098897B1 Compounds, compositions, and methods for stimulating neuronal growth and elongation |
| 06/09/2004 | EP1007043B1 Method for treatment of cns-involved lysosomal storage diseases |
| 06/09/2004 | DE20220902U1 Neuer Filmüberzug New film coating |
| 06/09/2004 | DE10320603A1 Verfahren zum Testen der Aktivität einer möglichen wirksamen Substanz, die die enzymatische Aktivität der Phospholipase A2 hemmen kann A method for testing the activity of a possible active substance which inhibit the enzymatic activity of phospholipase A2 can |